Kisspeptin-54 is the whole peptide — all 54 amino acids of it, and the form that actually circulates in human blood. Kisspeptin-10 is the last ten of those amino acids, cut away and used on their own. Same receptor, same working end, very different staying power: the long one lasts about 28 minutes in the bloodstream, the short one about four.
That gap explains most of what looks confusing about kisspeptin online. The studies people quote — the ones where a single injection matured eggs for IVF, the brain scans in people with low desire — used the long peptide. The version that turns up in compounded prescriptions is generally the short one.
Kisspeptin-10 has its own page. This one is about the long version, and why the difference matters before you read anyone's claims.
What kisspeptin-54 actually is
Your KISS1 gene makes a longer protein, and the body trims it down to a peptide 54 amino acids long with a capped tail. A team in Japan pulled it out of human placenta in 2001 and named it metastin, because the gene had first shown up in cancer work rather than fertility work (Ohtaki et al., Nature 2001).
The body makes shorter pieces too — 14, 13 and 10 amino acids long. All of them end in the same ten amino acids, and that shared tail is the part that fits the receptor. They open the same lock; what differs is how much peptide hangs off the key. The 54-residue version is the one that mainly circulates in people, which is why researchers reached for it first in humans.
Twenty-eight minutes versus four
Half-life is the time your body takes to clear half a dose — the plainest way to compare two versions of one molecule.
Six healthy men were given a 90-minute drip of kisspeptin-54 in a 2005 study, and their LH, FSH and testosterone all rose. Blood sampling put the half-life at 27.6 minutes (Dhillo et al., J Clin Endocrinol Metab 2005). Measured the same way, kisspeptin-10 came out at about four minutes (Jayasena et al., J Clin Endocrinol Metab 2011) — roughly seven times shorter.
| Length | Half-life in people | How it has been given | |
|---|---|---|---|
| Kisspeptin-54 | 54 amino acids | about 27.6 min | drip, or one injection under the skin |
| Kisspeptin-10 | 10 amino acids | about 4 min | mostly a drip or a bolus in a research unit |
Clearance is not the whole story, and a mouse experiment shows why. One injection of the long peptide kept LH up far longer than one of the short one. Repeating the short peptide every ten minutes for an hour still did not reproduce it. And only the long peptide switched on the GnRH neurons behind the blood-brain barrier (d'Anglemont de Tassigny et al., PLoS One 2017). The long one appears to reach somewhere the short one struggles to get to.
Which studies used kisspeptin-54
Nearly all the ones you have seen cited.
The IVF work. In 2014, 53 women in fertility treatment were given a single injection of kisspeptin-54 under the skin in place of the usual trigger, and their eggs were collected 36 hours later. Eggs matured at every dose tested, 92% went on to embryo transfer, and 23% had a clinical pregnancy (Jayasena et al., J Clin Invest 2014).
A follow-up studied 60 women at high risk of ovarian hyperstimulation syndrome, a serious complication in which the ovaries over-respond to fertility drugs. Eggs matured in 95% of them, and no one developed moderate, severe or critical OHSS (Abbara et al., J Clin Endocrinol Metab 2015). A 2017 trial in 62 women found that a second injection ten hours after the first lifted the share reaching a good egg yield from about 45% to about 71% (Abbara et al., Hum Reprod 2017).
The desire and brain-imaging work. Those trials used the long peptide as well, given as a 75-minute drip in a research unit. Thirty-two premenopausal women with low sexual desire completed one such crossover trial (Thurston et al., JAMA Netw Open 2022).
Notice what they have in common. A hospital. One dose, or two. A drip or a single supervised injection. Nobody in any of them was injecting kisspeptin at home for months on end.
What a 2026 study added
As of September 6, 2026, the day this article was written, the newest published human kisspeptin trial was dated August 3, 2026 — and it is about the short peptide. Fifteen healthy men took part in a randomised, single-blind, placebo-controlled study at Imperial College London. Given continuously under the skin for five days, kisspeptin-10 no longer lifted LH and FSH above placebo, though testosterone stayed up. Given eight hours on and sixteen hours off for twelve days, it kept those hormones up, and the receptor still answered a test dose at the end (Yeung et al., Eur J Endocrinol 2026).
That is the isoform question in a single experiment. The short peptide's limitation was never only that it clears quickly. It is also rhythm: a steady signal fades, an interrupted one holds.
This was physiology in healthy volunteers, not a treatment trial, and the infusion rates in it are facts about the study rather than a schedule to copy. It does show why timing belongs to a prescriber.
Which one is in a compounded prescription
Generally the short one, and the regulatory record says so. FDA's list of bulk substances that may present significant safety risks names kisspeptin-10 specifically — nominated for compounding under section 503A on September 29, 2023, with the agency citing a possible immunogenicity risk by some routes and limited safety information; the page was current as of April 22, 2026 (FDA). Kisspeptin-54 is not on it under its own name.
No kisspeptin medicine is FDA-approved at any peptide length, and a compounded kisspeptin preparation is not FDA-approved either. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. Regulatory status is one input into a prescribing decision rather than the whole of it, and a licensed provider may still prescribe a compounded preparation where they judge it appropriate — that decision is between you and your doctor.
Formulations vary by pharmacy and by prescription, so "which one am I getting" is a question for the visit. Kisspeptin through Promise is a compounded subcutaneous injection prescribed after review. What the peptide does in the body is covered in what does kisspeptin do; tolerability in kisspeptin side effects.
Why kisspeptin and PT-141 get mixed up
They come up in the same conversations, and they are not the same idea. Kisspeptin works upstream on the reproductive hormone axis: it signals the hypothalamus, and the hormones follow. PT-141 acts at melanocortin receptors in central pathways and does not touch that axis.
It matters here because the kisspeptin trials people cite for desire used the long peptide, given intravenously over about an hour in a research unit. A provider weighing the two is choosing between mechanisms, not ranking them.
What to do with this when you read a claim online
Check which peptide the claim rests on. A page selling a vial that quotes egg-maturation results or brain scans is quoting studies of the long peptide, given in a hospital, usually through a drip. That is not an argument against kisspeptin — it is an argument for knowing what you are reading.
A licensed provider reviews every request, prescribes only where it is appropriate for you, and can decline — not everyone qualifies. The isoform question is a reasonable one to bring to that review.
This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation. Talk to a licensed clinician about your own health.